While serotonin 5-HT1A receptor (5-HT1AR) agonists reduce l-DOPA-induced dyskinesias
(LID) by normalizing activity in the basal ganglia neurocircuitry, recent evidence suggests …

Convergent evidence suggests that serotonin 5-HT1A receptor (5-HT1AR) agonists reduce l-
DOPA-induced dyskinesia by auto-regulating aberrant release of l-DOPA-derived dopamine …

Abstract l-DOPA remains the benchmark treatment for Parkinson's disease (PD) motor
symptoms, but chronic use leads to l-DOPA-induced dyskinesia (LID). The serotonin (5-HT) …

5-HT1 receptor agonists have been shown to reduce abnormal involuntary movements
(AIMs) in the rat and monkey models of l-DOPA-induced dyskinesia. Different mechanisms …

Abstract Rationale Serotonin 1A receptor (5-HT1AR) agonists reduce l-DOPA-induced
dyskinesia and enhance motor function in experimental and clinical investigations of …

Abstract Chronic l‐3, 4‐dihydroxyphenylalanine (L‐DOPA) pharmacotherapy in Parkinson's
disease is often accompanied by the development of abnormal and excessive movements …

Appearance of dyskinesia is a common problem of long-term l-DOPA treatment in
Parkinson's disease patients and represents a major limitation for the pharmacological …

Selective activation of 5-HT1 receptors has been shown to produce near to full suppression
of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease; however, a …

Clinical and experimental studies implicate the use of serotonin (5‐HT) 1A receptor agonists
for the reduction of l‐3, 4‐dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia (LID) …

Serotonin 1A receptor (5-HT1AR) agonists have emerged as valuable supplements to l-
DOPA therapy, demonstrating that they can decrease side effects and enhance motor …